血浆外泌体miR-203a-3p是评估乳腺癌进展的潜在液体活检标志物

核心信息

  • 论文英文标题: Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients
  • 期刊: Breast Cancer-Targets and Therapy
  • 发表年份: 2024
  • DOI: 10.2147/BCTT.S478328
  • PMID/PMCID: 39310782; PMC11416789

研究概览

Cox regression analyses and survival analyses were performed on candidate miRNAs to explore their prognostic value (n = 848). Our findings suggested that plasma exosomal miR-203a-3p could hold potential as a liquid biopsy marker for evaluating BC progression in patients.

核心发现

We found that only miR-203a-3p was progressively elevated with BC progression and was associated with poor prognosis in the TCGA dataset.

Its potential target genes were enriched in pathways related to tumor progression, and the downregulation of 48 of these genes was associated with poor prognosis.

More importantly, plasma exosomal miR-203a-3p was also found to gradually increase with BC progression, and its expression was positively correlated with miR-203a-3p in BC tissues.

This result suggests that plasma exosomal miR-203a-3p may reflect the expression of miR-203a-3p in tumor tissues and serve as a potential liquid biopsy marker for monitoring BC progressions.

研究设计

In the TCGA database, we first screened for miRNAs significantly associated with BC progression by comparing miRNA expression in para-carcinoma tissues, stage I BC tissues, and stage II-III BC tissues (n = 1026).

Cox regression analyses and survival analyses were performed on candidate miRNAs to explore their prognostic value (n = 848).

KEGG, GO, and PPI analyses were used to identify enriched pathways associated with cancer.

Echo Biotech 角色

血浆外泌体分离鉴定及miRNA测序分析

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Plasma Exosome miR-203a-3p is a Potential Liquid Biopsy Marker for Assessing Tumor Progression in Breast Cancer Patients Breast Cancer-Targets and Therapy. 2024. DOI: 10.2147/BCTT.S478328. PMID/PMCID: 39310782; PMC11416789.